The relative therapeutic effects of vidarabine (9-,-D-arabinofuranosyladenine), cyclaradine (the adenosine deaminase-resistant carbocyclic analog of vidarabine), and cyclaradine-5'-methoxyacetate in the parenteral treatment of systemic herpes simplex virus type 1 infections in Swiss mice were determined. Among control mice inoculated intraperitoneally with virus, a mortality rate of 95% was observed. The intraperitoneal administration of nontoxic doses of vidarabine (125 to 250 mg/kg per day) or cyclaradine (113 to 450 mg/kg per day), by daily injections for 7 days beginning 4 h after virus inoculation, reduced mortality to 0 to 10%, Amnong control animals inoculated intracerebrally with 32 50% lethal doses of virus, 100%to mortality was observed, with a mean survival time of 4.6 days.
Treatment with either drug at equimolar dose levels ranging from ca. 32 to 750 mg/kg per day produced significant (P < 0.0005), dose-dependent increases in the mean survival time of animals dying of herpesvirus encephalitis. Mice inoculated intracerebraily with 10 50o lethal doses of virus exhibited 97% mortality and a mean survival time of 5.5 to 6.4 days. Treatment with vidarabine, cyclaradine, or cyclaradine-5'-methoxyacetate significantly increased the mean survival time of dying animals and, at doses ranging from 250 to 750 mg/kg per day, produced significant increases in survival. The three drugs displayed equivalent antiviral efficacy in vivo. Drug toxicity (measured by weight loss) was not detected in mice treated with cyclaradine or cyclaradine-5'-methoxyacetate at 750 mg/kg per day, whereas severe toxicity (weight loss of -3 g) was observed in mice treated with vidarabine at an equivalent dose level. Thus, cyclaradine or its 5'-methoxyacetic acid ester may possess some advantage over vidarabine in the treatment of severe herpesvirus infections and should therefore be considered for clinical trials in humans.
The antiviral drug vidarabine (9-p-D-arabinofuranosyladenine; ara-A) is highly effective in the systemic treatment of herpes simplex virus (HSV) encephalitis both in laboratory animals (11, 12, 17, 25, 29, 30) and in humans (33, 34, 36, 37) . This clinically effective purine nucleoside analog is rapidly deaminated in biological systems by the enzyme adenosine deaminase (2, 4, 6, 9, 40) . Since the deamination product, 9-p-Darabinofuranosylhypoxanthine, is considerably less potent than the parent compound (3-5, 13, 16, 19, 27, 28, 31) , attempts have been made in recent years to develop analogs or derivatives of ara-A that are deaminase resistant (23 analog of ara-A (cyclaradine; Fig. 1 ) and the significant activity of this adenosine deaminaseresistant, hydrolytically stable analog of ara-A against HSV type 1 (HSV-1) and vaccinia virus in cell cultures (32) . Like ara-A (24), cyclaradine was found to inhibit the replication of Gross murine leukemia virus in vitro (23 Statistical evaluation. Data were subjected to the appropriate statistical test for the determination of the levels of significance of differences observed. To compare the mortality of untreated and drug-treated mice, we evaluated the data by the chi-square test with the Yates correction. To compare the differences in mean survival time observed between virus-infected control (untreated) and virus-infected, drug-treated mice, we evaluated the data by the Student t test. A P value of <0.05 was considered indicative of a statistically significant difference.
RESULTS
Efficacy of cyclaradine in mice inoculated i.p. with HSV-1. The significant therapeutic effect of cyclaradine against lethal HSV-1 infections in mice, after i.p. inoculation of virus, was readily demonstrated (Table 1) . Cyclaradine was found to be as effective as ara-A in reducing mortality in the virus-infected animals. Whereas 95% of the virus-infected control (untreated) mice died, with a mean survival time of 8.4 days, systemic treatment with ara-A reduced the mortality to 0 to 10% when the drug was administered i.p. at nontoxic doses once a day for 7 days starting 4 h after virus inoculation. Likewise, cyclaradine was also significantly effective (P < 0.0005) in decreasing the mortality to 0 to 10% when administered i.p. to infected animals at nontoxic doses of between 112.5 and 450 mg/kg per day on the same treatment schedule. Cyclaradine at a dose level of 900 mg/kg per day (once daily for 7 days) was apparently not lethally toxic for uninfected animals, but failure to gain weight was noted. The same dose level proved to be toxic for HSV-infected mice, with a mean weight loss of 1.7 g. The mean survival time for HSV-infected mice was significantly shortened (P < 0.005) to 4.3 days. The LD10 for ara-A on the same schedule was ca. 600 mg/kg per day.
Efficacy of cyclaradine and its 5'-methoxyacetic acid ester in mice inoculated i.c. with HSV-1. We compared the therapeutic activities of ara-A and cyclaradine at equimolar dose levels against lethal HSV-1 infections in mice after i.c. inoculation with 32 LD50 of virus. This is an extremely severe test for any antiherpesvirus drug, including ara-A. All of the virus-infected control (untreated) mice died with a rapidly progressive and fulminating herpesvirus encephalitis, with a c Probability that the observed increase in survivor number (chi-square test) or the observed increase or reduction in mean survival time (Student t test) was due to chance: *, <0.0005; **, <0.001; t, <0.005; X, >0.10. A P value of <0.05 was considered a significant difference; a P value of <0.001 was considered a conclusive difference.
mean survival time of 4.6 days ( Table 2 ). In this model system, treatment with ara-A or cyclaradine resulted in only a maximum 30% survival rate among the virus-infected, drug-treated animals. This represented a statistically questionable (P < 0.1) increase in the number of survivors compared with the virus-infected control (untreated) group. However, both compounds, at dose levels ranging from ca. 32 to 750 mg/kg per day, were found to produce highly significant (P < 0.0005) dose-dependent increases in the mean survival times of treated mice dying with herpesvirus encephalitis. These two compounds, tested at equimolar doses, appeared to exhibit essentially equivalent antiviral activity in this in vivo assay system. No significant weight loss or obvious drug toxicity was observed in uninfected animals treated with cyclaradine at a dose of 750 mg/kg per day (once daily for 7 days), but failure to gain weight was observed when compared with the untreated controls. However, significant weight loss was observed in uninfected animals treated with ara-A at the equivalent dose (755.3 mg/kg per day) on the same schedule (Table 2) , and severe toxicity in terms of weight loss (.3-g loss) was seen in the HSV-infected animals treated with ara-A at this same dose level.
Mice inoculated i.c. with a lower challenge dose of 10 LD50 of HSV-1 exhibited a mortality rate of 97% and a mean survival time of 6.4 days (Table 2 ). Treatment with ara-A, cyclaradine, or cyclaradine-5'-methoxyacetate significantly increased the mean survival time of dying animals and, at the higher doses, produced highly significant (P < 0.0005) increases in the numbers of survivors when compared with the virus-infected control (untreated) group. Toxicity, in terms of weight loss, was not detected in mice treated with cyclaradine at 750 mg/kg per day or with cyclaradine-5'-methoxyacetate at 600 mg/kg per day, whereas significant toxicity (weight loss of 3 g) was observed in the ara-A-treated mice at the equivalent dose level (Table 2) .
In another experiment, control mice inoculated i.c. with 10 LD50 of HSV-1 rapidly developed encephalitis and, again, 97% of the animals died, with a mean survival time of 5.5 days (Table 2) . Cyclaradine-5'-methoxyacetate treatment resulted in a significant (P < 0.0005) increase in the mean survival time of dying animals, similar to that obtained with ara-A treatment. Activity was observed with this cyclaradine derivative at dose levels ranging from 62.5 to 750 mg/kg per day (once daily for 7 days), and no drug toxicity was encountered.
DISCUSSION
Herpesvirus encephalitis in humans is characterized by an extremely severe, devastating infection of the brain and central nervous system. In children and adults, it is usually caused by HSV-1. In neonates, however, herpesvirus encephalitis usually results from dissemination of virus acquired from maternal genital infections, and these are usually caused by HSV-2 (14) . If left untreated, the mortality rate associated with this disease is approximately 70 to 80% (33, 34, 36, 38 a 12-h period for 10 days, was found to significantly reduce the mortality due to HSV-1 encephalitis from 70 to ca. 28% among those patients (36) . Another collaborative study was recently completed in which ara-A was also evaluated in newborn infants with localized central nervous system infection or disseminated disease. The overall mortality of these infected VOL. 24, 1983 on July 6, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHEMOTHER.
neonates was reduced from 75 to 38% with ara-A therapy (35) . Despite these impressiveaidvances and recent successes of antiviral chemotherapy in the treatment of disseminated herpesvirus infections, including HSV encephalitis, there is, nevertheless, still a real need for better therapeutic agents or for improved therapy with existing agents (10, 37) .
One ofthe major problems associated with the systemic administration of ara-A to patients is its relative insolubility in water, which necessitates the use of large volumes of fluid for its intravenous delivery. The use of the more watersoluble derivative, ara-AMP, which is undergoing clinical trials for efficacy against herpesvirus infections in humans, has been suggested as a solution to this particular problem (10, 37, 38) . Another probiem with ara-A lies in the fact that this purine. nucleoside analog is rapidly deaminated in biological systems by the enzyme adenosine deamninase to yield a considerably less potent antiviral agent, 9-,3-D-arabinofuranosylhypoxanthine (16) . Attempts to circumvent the loss of activity of ara-A through deamination to 9-,3-D-arabinofuranosylhypoxanthine have involved the use of potent adenosine deaminase inhibitors, such as 2'-deoxycoformycin (39) and erythro-9-(2-hydroxy-3-nonyl)adenine (18) , in combination with ara-A or ara-AMP (3, 15, 20, 21, 23, 28) . These studies have provided experimental data which indicate that the antiviral potency of ara-A can be greatly increased by the simultaneous administration of either of these potent enzyme inhibitors. However, this approach involves the use of a second drug in combination with ara-A or ara-AMP, and deleterious problems could possibly arise from the marked inhibition of adenosine deaminase activity in a patient treated with such combinations. An (1, 22, 26) . The chemical synthesis of cyclaradine was facilitated through the use of a simple, high-yield route to carbocyclic nucleoside analogs developed by Daluge and Vince (7, 8) .
Data presented in this report indicate that cyclaradine possesses potent activity against HSV-1 in vivo. The therapeutic efficacy of this new analog of ara-A in the treatment of HSV-1 encephalitis in mice appears to be comparable to that demonstrated by ara-A under identical assay conditions, even though cyclaradine is a racemic mixture of enantiomers and presumably only one of the enantiomers is responsible for the antiviral effects observed. Significant increases in the numbers of survivors and in the mean survival time of animals dying of HSV-1 encephalitis were reproducibly obtained with nontoxic dose levels of cyclaradine or its 5'-methoxyacetic acid ester when compared with virus-infected controls (untreated). No toxicity, in terms of weight loss, was ever detected in mice treated with cyclaradine or with cyclaradine-5'-methoxyacetate at a dose level of 750 mg/kg per day, whereas severe toxicity (weight loss of -3 g) was observed in the ara-A-treated mice at the equivalent dose level. Thus, cyclaradine may possess some advantage over ara-A in the treatment of herpesvirus infections and should therefore be considered a promising new drug for possible clinical use in the therapy of HSV encephalitis and disseminated disease in newborn infants.
